Clinical predictors of atrial fibrillation recurrence in the Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico-Atrial Fibrillation (GISSI-AF) trial

American Heart Journal

Volumn 159, Issue 5, 2010, Pages 857-863

  Disertori, Marcello ^a   Lombardi, Federico ^b   Barlera, Simona ^c   Latini, Roberto ^c   Maggioni, Aldo P ^d   Zeni, Prisca ^a   Di Pasquale, Giuseppe ^e   Cosmi, Franco ^f   Franzosi, Maria Grazia ^c  

^a SANTA CHIARA HOSPITAL   (Italy)

^b SAN PAOLO HOSPITAL   (Italy)

^c MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^d ANMCO RESEARCH CENTER   (Italy)

^e MAGGIORE HOSPITAL   (Italy)

^f Department of Internal Medicine   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALDOSTERONE ANTAGONIST; AMIODARONE; ANTIARRHYTHMIC AGENT; ANTICOAGULANT AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIGITALIS; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PLACEBO; VALSARTAN;

AGED; ARTICLE; CARDIOVERSION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; HEART ATRIUM FIBRILLATION; HEART RATE; HUMAN; ITALY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; RECURRENCE RISK; RISK FACTOR; SINUS RHYTHM;

AGED; AMIODARONE; ANTI-ARRHYTHMIA AGENTS; ANTIHYPERTENSIVE AGENTS; ATRIAL FIBRILLATION; DIURETICS; ELECTROPHYSIOLOGIC TECHNIQUES, CARDIAC; FEMALE; HUMANS; MALE; MIDDLE AGED; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RECURRENCE; RISK FACTORS; TETRAZOLES; VALINE;

EID: 77951557990     PISSN: 00028703     EISSN: 10976744     Source Type: Journal    
DOI: 10.1016/j.ahj.2010.02.016     Document Type: Article

References (38)

1. Kannel W.B., Abbott R.D., Savage D.D., et al. Epidemiologic features of atrial fibrillation: the Framingham study. N Engl J Med 306 (1982) 1018-1022
2. Go A.S., Hylek E.M., Phillips J.A., et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention; the Anticoagulation and Risk Factors in Atrial Fibrillation (ATRIA) study. JAMA 285 (2001) 2370-2375
3. Pozzoli M., Cioffi G., Traversi, et al. Predictors of primary atrial fibrillation and concomitant clinical and hemodynamic changes in patients with chronic heart failure: a prospective study in 344 patients with baseline sinus rhythm. J Am Coll Cardiol 32 (1998) 197-204
4. Dries D.L., Exner D.V., Gersh B.J., et al. Atrial fibrillation is associated with an increased risk for mortality and heart failure progression in patients with asymptomatic and symptomatic left ventricular systolic dysfunction: a retrospective analysis of the SOLVD trials. Studies of Left Ventricular Dysfunction. J Am Coll Cardiol 32 (1998) 695-703
5. Mathew J., Hunsberger S., Fleg J., et al. Incidence, predictive factors, and prognostic significance of supraventricular tachyarrhythmias in congestive heart failure. Chest 118 (2000) 914-922
6. Roy D., Talajic M., Dorian P., et al., for the Canadian Trial of Atrial Fibrillation Investigators. Amiodarone to prevent recurrence of atrial fibrillation. Canadian Trial of Atrial Fibrillation Investigators. N Engl J Med 342 (2000) 913-920
7. Lafuente-Lafuente C., Mouly S., Longàs-Tejero M.A., et al. Antiarrhythmic drugs for maintaining sinus rhythm after cardioversion of atrial fibrillation. Arch Intern Med 166 (2006) 719-728
8. Kober L., Torp-Pedersen C., McMurray J.J., et al. Increased mortality after dronedarone therapy for severe heart failure. N Engl J Med 358 (2008) 2678-2687
9. Cappato R., Calkins H., Chen S.A., et al. Worldwide survey on the methods, efficacy, and safety of catheter ablation for human atrial fibrillation. Circulation 111 (2005) 1100-1105
10. Fuster V., Rydén L.E., Cannom D.S., et al. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation-executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation). Eur Heart J 27 (2006) 1979-2030
11. Hohnloser S., and Kuck K.H. Rhythm or rate control in atrial fibrillation. Pharmacological Intervention in Atrial Fibrillation (PIAF). Lancet 356 (2000) 1789-1794
12. Wyse D.G., Waldo A.L., Di Marco J.P., et al. Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) investigators. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med 347 (2002) 1825-1833
13. Van Gelder I.C., Hagens V.E., Bosker H.A., et al. Rate Control versus Electrical Cardioversion for Persistent Atrial Fibrillation study Group (RACE). A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation. N Engl J Med 347 (2002) 1834-1840
14. Roy D., Talajic M., Nattel S., et al. Rhythm control versus rate control for atrial fibrillation and heart failure. N Engl J Med 358 (2008) 2677
15. Duytsschaever M., Haerynck F., Tavernier R., et al. Factors influencing long term persistence of sinus rhythm after first electrical cardioversion for atrial fibrillation. PACE 21 (1998) 284-287
16. Lehto M., and Kala R. Persistent atrial fibrillation: a population based study of patients with their first cardioversion. Int J Cardiol 92 (2003) 145-150
17. Dahlin J., Svendsen P., and Gadsboll N. Poor maintenance of sinus rhythm after electrical cardioversion of patients with atrial fibrillation or flutter: a 5-year follow-up of 268 consecutive patients. Scand Cardiovasc J 37 (2003) 324-328
18. Raitt M.H., Volgman A.S., Zoble R.G., et al. Prediction of the recurrence of atrial fibrillation after cardioversion in the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study. Am Heart J 151 (2006) 390-396
19. Boriani G., Diemberger I., Biffi M., et al. Electrical cardioversion for persistent atrial fibrillation or atrial flutter in clinical practice: predictors of long-tem outcome. Int J Clin Pract 61 (2007) 748-756
20. Soran H., Younis N., Currie P., et al. Influence of diabetes on the maintenance of sinus rhythm after successful direct current cardioversion in patients with atrial fibrillation. Q J Med 101 (2008) 181-187
21. Kinoshita M., Herges R.M., Hodge D.O., et al. Role of smoking in the recurrence of atrial arrhythmias after cardioversion. Am J Cardiol 104 (2009) 678-682
22. Friberg L., Hammar N., Edvarsson N., et al. The prognosis of patients with atrial fibrillation is improved when sinus rhythm is restored: report from the Stockholm Cohort of Atrial Fibrillation (SCAF). Heart 95 (2009) 1000-1005
23. Hegbom F., Tveit A., Grundvold I., et al. Effects of angiotensin receptor blockade on serial P-wave signal-averaged electrocardiograms after electrical cardioversion of persistent atrial fibrillation. Europace 11 (2009) 1301-1307
24. The GISSI-AF Investigators. Valsartan for prevention of recurrent atrial fibrillation. N Engl J Med 360 (2009) 1606-1617
25. Disertori M., Latini R., Maggioni A.P., et al. Rationale and design of the GISSI-Atrial Fibrillation Trial: randomized, prospective, multicenter study on the use of valsartan, an angiotensin II ATI-receptor blocker, in the prevention of atrial fibrillation recurrence. J Cardiovasc Med 7 (2006) 29-38
26. Oral H., Souza J.J., Michaud G.F., et al. Facilitating transthoracic cardioversion of atrial fibrillation with ibutilide pretreatment. N Engl J Med 340 (1999) 1849-1854
27. Lombardi F., Tarricone D., Tundo F., et al. Autonomic nervous system and paroxysmal atrial fibrillation: a study based on the analysis of RR interval changes before, during and after paroxysmal atrial fibrillation. Eur Heart J 25 (2004) 1242-1248
28. Lu Z., Scherlag B.J., Lin J., et al. Autonomic mechanism for initiation of rapid firing from atria and pulmonary veins: evidence by ablation of ganglionated plexi. Cardiovasc Res 84 (2009) 245-252
29. Schnabel R.B., Sullivan L.M., Levy D., et al. Development of a risk score for atrial fibrillation (Framingham Heart Study): a community-based cohort study. Lancet 373 (2009) 739-745
30. Humphries K.H., Lee M., Sheldon R., et al. Statin use and recurrence of atrial fibrillation after successful cardioversion. Am Heart J 154 (2007) 908-913
31. Maggioni A.P., Fabbri G., Lucci D., et al. Effects of rosuvastatin on atrial fibrillation occurrence: ancillary results of the GISSI-AF trial. Eur Heart J 30 (2009) 2327-2336
32. Madrid A.H., Bueno M.G., Rebollo J.M., et al. Use of irbesartan to maintain sinus rhythm in patients with long-lasting persistent atrial fibrillation: a prospective and randomized study. Circulation 106 (2002) 331-336
33. Yin Y., Dalal D., Liu Z., et al. Prospective randomized study comparing amiodarone vs. amiodarone plus losartan vs. amiodarone plus perindopril for prevention of atrial fibrillation recurrence in patients with lone paroxysmal atrial fibrillation. Eur Heart J 27 (2006) 1841-1846
34. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 288 (2002) 2981-2997
35. Emara M.K., and Saadet A.M. Transient atrial fibrillation in hypertensive patients with thiazide induced hypokalemia. Postgrad Med J 62 (1986) 1125-1127
36. Papademetriu V., Burris J.F., Notargiacomo A., et al. Thiazide therapy is not a cause of arrhythmia in patients with systemic hypertension. Arch Intern Med 148 (1988) 1272-1276
37. Law M.R., Wald N.J., Morris J.K., et al. Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials. BMJ 326 (2003) 1427-1435
38. Mancia G., De Baker G., Dominiczak A., et al. Guidelines for the management of arterial hypertension. The Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 28 (2007) 1462-1536